Overview

Resistant Depression Treatment Market Introduction

Resistant Depression Treatment Market is foreseen to value over US$ 1 billion by the end of 2027 and register at a CAGR of 3% during the forecast period of 2020-2027.
According to the World Health Organization around 300 million people around the world have depression. At present switching antidepressants, increasing dosages, allowing more time for medications to work, augmented medication for other conditions, neuro-stimulation and psychotherapy are some of the ways for resistant depression treatment. However, burgeoning demand to counter the therapeutic challenge resulted in the emergence of innovative resistant depression treatment. Recently ketamine-based depression treatments are gaining preference as major biopharmaceutical companies receive a green signal from the Food and Drug Administration (FDA).

Some of the factors that are driving the global resistant depression treatment market include:
• Rise in demand for antidepressant treatment due to increasing mental health issues
• Burden on the healthcare system due to nonresponding patients to a combination of antidepressants
• Ageing population as well as increased anxiety and depression syndrome in the millennials
• Ineffectiveness of antidepressants due to an individual’s genetic composition
• Exposure to addictive substances that prevent antidepressant medications to positively treat patients

Stigma related to depressive disorder treatments, patent expiration, fear of drug withdrawals, high cost, lack of substantial clinical trials to gauge the efficacy of resistant depression medicines contribute as the major restraints to the global resistant depression treatment market.
High prevalence of depression and mental disorders with substantial treatment resistance in Europe and North America are indicative of progressive growth of the market. Increasing awareness about mental health and related treatments are anticipated to create greater opportunities in the near future amongst the emerging nations in the Asia-Pacific and rest of the world.

Resistant Depression Treatment Key Market Players:
Roche Holding, Johnson & Johnson, Merck & CO., Novartis AG, Pfizer Inc., Janssen Pharmaceuticals, Seelos Therapeutics, Bristol-Myers Squibb, GlaxoSmithKline plc and others

Resistant Depression Treatment Market

Resistant Depression Treatment Market Segmentation :
By Drug Type
• Selective serotonin reuptake inhibitors
• Serotonin-norepinephrine reuptake inhibitors
• Tricyclic antidepressants
• Monoamine oxidase inhibitors
• Atypical agents
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Mail Order Pharmacies
By Region
• North America
• Latin America
• Europe
• Asia Pacific
• Rest of the World
Competitive Landscape:
• Tier 1 players - established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the global resistant depression treatment market on the basis of drug type, distribution channel, and region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East
• To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
• Profiling of companies to evaluate their market shares, strategies, financials and core competencies